Clinical Handbook of Psychotropic Drugs for Children and Adolescents

Clinical Handbook of Psychotropic Drugs for Children and Adolescents

By Tyler R. Black (Editor), Dean Elbe (Editor), Ian R. McGrane (Editor), Ric M. Procyshyn (Editor)

Format: PDF  
Availability: Instant download


The Clinical Handbook of Psychotropic Drugs for Children and Adolescents has become a standard reference and working tool for psychiatrists, pediatricians, psychologists, physicians, pharmacists, nurses, and other mental health professionals. - Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions…) for a quick overview of treatment options - Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, nursing implications, and much more – all you need to know for each class of drug - Potential interactions and side effects summarized in comparison charts - With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek - Clearly written patient and caregiver information sheets for download as printable PDF files This book is a must for all mental health professionals working with children and adolescents who need an up-to-date, easy-to use, comprehensive summary of all the most relevant information about psychotropic drugs. New in this edition: - Drugs for ADHD thoroughly revised and updated - Antipsychotics with many changes and additions, including fully revised lab tests/monitoring - Antidepressants fully revised, including new sections on irreversible MAO-B inhibitor and serotonin modulator and stimulator (SMS), revised frequency of adverse effects table and switching strategies recommendations - Hypnotics completely revised - Mood stabilizers fully revised and a new toxicity comparison table added - Drugs of abuse and treatment of substance use disorder comprehensively revised - New unapproved treatments with significant updates, including: anti-inflammatories and NMDA agents in anxiety/OCD, cannabis use, and irritability of autism - New agents include: TGAs N-arylpiperazine (brexpiprazole) and phenylpiperazine (cariprazine), hypnotics orexin receptor antagonist (hypnotic suvorexant) and selective melatonin agonist (tasimelteon), antidepressant bisarylsulfanyl amine (vortioxetine) - New formulations and trade names include: Adasuve, Alprazolam Intensol, Aptensio XR, Aristada, Belbuca, Belsomra, Brintellix, Bunavail, Cotempla XR-ODT, Dyanavel XR,Eldepryl, EMSAM, Evekeo, Hemangeol, Hetlioz, Innopran XL, Invega Trinza, Khedezla, Metadol-D, Mydayis, NyQuil, Quillichew ER, Quillivant XR, Rexulti, Som-Pam, Tegretol (liquid), Trintellix, Versacolz, Vraylar, Vyvanse, Zelapar, Zenzedi

Ric M. Procyshyn